Krystal Total Debt To Capitalization from 2010 to 2024

KRYS Stock  USD 186.60  4.31  2.36%   
Krystal Biotech Total Debt To Capitalization yearly trend continues to be comparatively stable with very little volatility. Total Debt To Capitalization will likely drop to 0 in 2024. From the period from 2010 to 2024, Krystal Biotech Total Debt To Capitalization quarterly data regression had r-value of (0.87) and coefficient of variation of  109.16. View All Fundamentals
 
Total Debt To Capitalization  
First Reported
2010-12-31
Previous Quarter
0.00188947
Current Value
0.001795
Quarterly Volatility
0.44359234
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 23.8 M, Interest Income of 23.8 M or Depreciation And Amortization of 5.3 M, as well as many indicators such as Price To Sales Ratio of 72.59, Dividend Yield of 0.0 or PTB Ratio of 4.11. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
  
Check out the analysis of Krystal Biotech Correlation against competitors.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Latest Krystal Biotech's Total Debt To Capitalization Growth Pattern

Below is the plot of the Total Debt To Capitalization of Krystal Biotech over the last few years. It is Krystal Biotech's Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Krystal Biotech's overall financial position and show how it may be relating to other accounts over time.
Total Debt To Capitalization10 Years Trend
Slightly volatile
   Total Debt To Capitalization   
       Timeline  

Krystal Total Debt To Capitalization Regression Statistics

Arithmetic Mean0.41
Geometric Mean0.04
Coefficient Of Variation109.16
Mean Deviation0.43
Median0.03
Standard Deviation0.44
Sample Variance0.20
Range0.8627
R-Value(0.87)
Mean Square Error0.05
R-Squared0.75
Significance0.000029
Slope(0.09)
Total Sum of Squares2.75

Krystal Total Debt To Capitalization History

2024 0.001795
2023 0.001889
2021 0.00298
2020 0.0274
2017 0.00236

About Krystal Biotech Financial Statements

Krystal Biotech shareholders use historical fundamental indicators, such as Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.